Immunome (NASDAQ:IMNM) Issues Quarterly Earnings Results

Immunome (NASDAQ:IMNM) issued its quarterly earnings results on Wednesday. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16), Zacks reports. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.

Immunome Trading Up 2.5 %

NASDAQ:IMNM traded up $0.21 on Wednesday, hitting $8.57. The company had a trading volume of 522,479 shares, compared to its average volume of 810,302. The stock has a market capitalization of $683.69 million, a price-to-earnings ratio of -1.06 and a beta of 1.93. The firm has a 50 day moving average of $9.89 and a two-hundred day moving average of $11.66. Immunome has a 52 week low of $8.34 and a 52 week high of $26.70.

Wall Street Analyst Weigh In

A number of research analysts recently commented on IMNM shares. Lifesci Capital started coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Monday, March 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $27.17.

Insider Activity

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was purchased at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the purchase, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 8.60% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.